Gynecologic Cancer clinical trials at University of California Health
3 in progress, 2 open to eligible people
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
open to eligible people ages 18 years and up
This is an open-label, multicenter, First-In-Human (FIH), Phase 1a/1b study of PY159 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to Standard Of Care (including Checkpoint Inhibitors, if approved for that indication).
at UCSF
A Study of PY314 in Subjects With Advanced Solid Tumors
open to eligible people ages 18 years and up
This is an open-label, multicenter, first in human, Phase 1a/1b study of PY314 in subjects with locally advanced (unresectable) and/or metastatic solid tumors that are refractory or relapsed to standard of care (including pembrolizumab, if approved for that indication).
at UCSD
A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor
Sorry, currently not accepting new patients, but might later
This is an open-label, Phase 1b/2 study to determine the recommended dose of lucitanib in combination with nivolumab in patients with an advanced solid tumor (Phase 1b); followed by evaluation of the safety and efficacy of lucitanib and nivolumab in patients with an advanced gynecological solid tumor (Phase 2) and evaluate the effects of dosing under fasting or fed state (Food Effect)
at UCLA UCSD
Last updated: